TipRanks
Advertisement
Advertisement
Cytek: Solid Q2 Beat and Modest Outlook Raise, But Regional and Profitability Risks Justify Hold Rating
PremiumRatingsCytek: Solid Q2 Beat and Modest Outlook Raise, But Regional and Profitability Risks Justify Hold Rating
2M ago
Cytek Biosciences reports Q2 EPS (9c), consensus (2c)
Premium
The Fly
Cytek Biosciences reports Q2 EPS (9c), consensus (2c)
2M ago
Cytek Biosciences sees FY26 revenue $207M-$212M, consensus $208.83M
Premium
The Fly
Cytek Biosciences sees FY26 revenue $207M-$212M, consensus $208.83M
2M ago
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
PremiumThe FlyCytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
5M ago
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Premium
The Fly
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
5M ago
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures
Premium
Company Announcements
Cytek Biosciences Faces Rising Risk From U.S.–China Trade Tensions and Tariff Pressures
5M ago
Cytek Biosciences price target raised to $5 from $4 at TD Cowen
PremiumThe FlyCytek Biosciences price target raised to $5 from $4 at TD Cowen
9M ago
Cytek Biosciences assumed with an Equal Weight at Morgan Stanley
Premium
The Fly
Cytek Biosciences assumed with an Equal Weight at Morgan Stanley
10M ago
Cytek Biosciences price target lowered to $7.50 from $8 at Piper Sandler
Premium
The Fly
Cytek Biosciences price target lowered to $7.50 from $8 at Piper Sandler
11M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―